MedTrace Logo

Time to Initiated Antitumor Therapy for Tumor Patients With COVID19 Infection

NCT06006845 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-08-23

No results posted yet for this study

Summary

The goal of this observational study is to study the safety of initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19. The main questions aims to answer are:

* Whether initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19 increases adverse events related to antitumor therapy.
* Whether initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19 increases risk of re-infection of COVID-19.
* How initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19 affects QoL of tumor patients

Participants will be asked to answer the question about:

* the severity and duration of COVID-19 symptoms
* the date of diagnosis of COVID-19
* the date of negative nucleic acid test
* the QoL of life before infection with COVID-19, during infection of COVID-19, after nucleic acid test negativity and receiving antitumor therapy

Conditions

Sponsors & Collaborators

  • The Seventh Affiliated Hospital of Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Bo Wang · The Seventh Affiliated Hospital of Sun Yat-sen University

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2023-02-01
Completion
2024-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06006845 on ClinicalTrials.gov